MY134123A - Citrate salt of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof - Google Patents

Citrate salt of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Info

Publication number
MY134123A
MY134123A MYPI20021725A MYPI20021725A MY134123A MY 134123 A MY134123 A MY 134123A MY PI20021725 A MYPI20021725 A MY PI20021725A MY PI20021725 A MYPI20021725 A MY PI20021725A MY 134123 A MY134123 A MY 134123A
Authority
MY
Malaysia
Prior art keywords
citrate salt
triazatetracyclo
pentaene
hexadeca
pharmaceutical compositions
Prior art date
Application number
MYPI20021725A
Other languages
English (en)
Inventor
Robert Rose Peter
Robert Williams Glenn
James Johnson Phillip
Theophilus Wint Lewin
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY134123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MY134123A publication Critical patent/MY134123A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
MYPI20021725A 2001-05-14 2002-05-13 Citrate salt of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof MY134123A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
MY134123A true MY134123A (en) 2007-11-30

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20021725A MY134123A (en) 2001-05-14 2002-05-13 Citrate salt of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Country Status (37)

Country Link
US (1) US6787549B2 (OSRAM)
EP (1) EP1390366B1 (OSRAM)
JP (1) JP4137645B2 (OSRAM)
KR (1) KR20040008175A (OSRAM)
CN (1) CN1509288A (OSRAM)
AP (1) AP1429A (OSRAM)
AR (1) AR035889A1 (OSRAM)
AT (1) ATE303386T1 (OSRAM)
BG (1) BG108344A (OSRAM)
CA (1) CA2446988A1 (OSRAM)
CZ (1) CZ20032917A3 (OSRAM)
DE (1) DE60205888T2 (OSRAM)
DO (1) DOP2002000390A (OSRAM)
DZ (1) DZ3503A1 (OSRAM)
EA (1) EA005529B1 (OSRAM)
EE (1) EE200300557A (OSRAM)
ES (1) ES2245731T3 (OSRAM)
GT (1) GT200200081A (OSRAM)
HR (1) HRP20030911A2 (OSRAM)
HU (1) HUP0304085A3 (OSRAM)
IL (1) IL157874A0 (OSRAM)
IS (1) IS6956A (OSRAM)
MA (1) MA27021A1 (OSRAM)
MX (1) MXPA03010365A (OSRAM)
MY (1) MY134123A (OSRAM)
NO (1) NO20035035D0 (OSRAM)
NZ (1) NZ528209A (OSRAM)
OA (1) OA12600A (OSRAM)
PA (1) PA8545001A1 (OSRAM)
PE (1) PE20021095A1 (OSRAM)
PL (1) PL366774A1 (OSRAM)
SK (1) SK13372003A3 (OSRAM)
TN (1) TNSN03112A1 (OSRAM)
UA (1) UA73421C2 (OSRAM)
UY (1) UY27287A1 (OSRAM)
WO (1) WO2002092597A1 (OSRAM)
ZA (1) ZA200307234B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00459B (me) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
PT1448235E (pt) 2001-11-30 2007-05-31 Pfizer Prod Inc Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno.
JP2006528237A (ja) * 2003-05-20 2006-12-14 ファイザー・プロダクツ・インク バレニクリンの医薬組成物
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2376499B1 (en) * 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
KR101673979B1 (ko) 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
JP2023520164A (ja) * 2020-03-16 2023-05-16 チョンドゥー サイマウント ファーマテック カンパニー リミテッド ５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00459B (me) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
EA200301120A1 (ru) 2004-02-26
EP1390366B1 (en) 2005-08-31
EA005529B1 (ru) 2005-04-28
AP1429A (en) 2005-06-13
AR035889A1 (es) 2004-07-21
GT200200081A (es) 2003-04-22
CN1509288A (zh) 2004-06-30
CZ20032917A3 (cs) 2004-07-14
SK13372003A3 (sk) 2004-08-03
DE60205888D1 (de) 2005-10-06
BG108344A (bg) 2004-12-30
ES2245731T3 (es) 2006-01-16
EE200300557A (et) 2004-04-15
HRP20030911A2 (en) 2004-02-29
PL366774A1 (en) 2005-02-07
JP2004529186A (ja) 2004-09-24
OA12600A (en) 2006-06-09
NO20035035L (no) 2003-11-13
TNSN03112A1 (fr) 2005-12-23
DE60205888T2 (de) 2006-07-06
PE20021095A1 (es) 2002-12-14
IL157874A0 (en) 2004-03-28
MA27021A1 (fr) 2004-12-20
KR20040008175A (ko) 2004-01-28
UA73421C2 (en) 2005-07-15
ZA200307234B (en) 2004-09-16
PA8545001A1 (es) 2003-09-05
DZ3503A1 (OSRAM) 2002-11-21
JP4137645B2 (ja) 2008-08-20
HUP0304085A2 (en) 2004-04-28
IS6956A (is) 2003-09-15
AP2002002522A0 (en) 2002-06-30
UY27287A1 (es) 2003-02-28
EP1390366A1 (en) 2004-02-25
US6787549B2 (en) 2004-09-07
NO20035035D0 (no) 2003-11-13
WO2002092597A1 (en) 2002-11-21
HUP0304085A3 (en) 2005-09-28
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
MXPA03010365A (es) 2004-03-16
NZ528209A (en) 2004-09-24
US20030149091A1 (en) 2003-08-07
DOP2002000390A (es) 2003-03-15

Similar Documents

Publication Publication Date Title
AP1429A (en) Citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]- hexadeca2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof.
AP1473A (en) Tartrate salts of 5,8,14-triazatetracyclo{10.3.1.0 .0] hexadeca2(11),3,5,7.9-pentaene and pharmaceutical compositions thereof.
DE60112609D1 (en) Pyrazolopyridine
PL370913A1 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
AU2003228770A8 (en) Substituted pyrazolopyrimidines
GB0114286D0 (en) Nucleoside Derivatives
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
ATE332301T1 (de) Antivirale pyrazolopyridin verbindungen
WO2002048148A3 (en) Pyrazolopyridine derivatives
MXPA04003192A (es) Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
IL164767A0 (en) 7-Aryl-3,9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertenision, cardiovascular or renal diseases
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE60201074D1 (en) Pyrazolopyridinderivate
WO2004058303A3 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
WO2001007418A3 (en) Ceramide analogs, process for their preparation and their use as antitumor agents
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
SE0100295D0 (sv) New compounds
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
SE0100296D0 (sv) New compounds
SE0100297D0 (sv) New compounds
HUP0402283A3 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine, process for their preparation and pharmaceutical compositions containing them
AP2001002179A0 (en) 2-Aminocarbonyl-9h-purine derivatives.